Malignant gliomas represent the most common primary brain tumor: more than 50% of them are glioblastoma multiforme (GBM). Photodynamic therapy may offer a very good chance of targeted destruction of infiltrating GBM cells, thus increasing the survival time and recurrence-free interval of GBM patients. Among photosensitizing agents, meta-tetrahydroxyphenylchlorin (m-THPC) is promising for the treatment of brain tumors. In previous studies, we investigated the transfection activity of dimyristoyl-sn-glycero-phosphatidylcholine (DMPC) liposomes, containing a cationic gemini surfactant, loaded with m-THPC on human colon adenocarcinoma and glioblastoma cell lines. In this paper, the uptake and the intracellular distribution of m-THPC, loaded in several formulations of cationic liposomes, were analyzed, by making a comparison with those obtained using the same chlorin in the pharmaceutical form (Foscan 1 ). Moreover, by cloning efficiency assay the potential therapeutic efficiency of chlorin delivered by liposome formulations was compared with that of the pharmaceutical compound, before and after irradiation with laser light at 652 nm. The obtained results indicated that cationic liposomes (i) transferred m-THPC in glioblastoma cells more efficiently than pharmaceutical formulation; (ii) significantly (p < 0.001) increased the m-THPC cytotoxic effect after laser irradiation; (iii) seemed to exert their cytotoxic action in the early phase of interaction with the cells, during adhesion to the plasma membrane. ' 2007 Wiley-Liss, Inc.Key words: cationic liposomes; photodynamic therapy; m-THPC; glioblastoma Malignant gliomas represent the most common primary brain tumor. With an incidence of 5 cases per 100,000 population per year, they are the fourth most common cause of cancer-related deaths and are among the most lethal cancers, with an overall survival length of less than 2 years. Moreover, more than 50% of them are glioblastoma multiforme (GBM; the most malignant brain tumor) that has a 30% survival rate at 1 year and less than 3% at 3 years. The great technical advances of diagnostic tools and operative technical management have reduced postoperative mortality and morbidity in patients with malignant gliomas, but the long-term prognosis is still poor. On this basis, many different adjuvant therapies have been developed. Among them, one the most promising is photodynamic therapy (PDT).
1-4Initiated by Diamond et al. 5 in 1972 and Signorelli et al. 6 in 1978, PDT is based on photochemical reactions between light and tumoral tissue selectively labeled with exogenous photosensitizing agents. Such reactions produce, at intracellular level, vast amounts of free radicals (singlet oxygen, superoxide), which determine tumor cell destruction. 7,8 PDT may offer a very good chance of targeted destruction of infiltrating GBM cells; this could increase survival time and recurrence-free interval of GBM patients.
9Among photosensitizing agents, meta-tetrahydroxyphenylchlorin (m-THPC) is promising for the treatment of brain tumor...